Home › Multiple Sclerosis › Connecticut › New Haven
Multiple Sclerosis clinical trials in New Haven, CT
4 studies for Multiple Sclerosis are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
RecruitingPhase 1Healthy volunteers welcome
- Yale University PET Center, New Haven
Identifying and Characterizing Preclinical MS
RecruitingObservational studyHealthy volunteers welcome
- Yale University, North Haven · 7 mi away
Intestinal Immunity in Neurologic Disease
RecruitingObservational studyHealthy volunteers welcome
- Yale MS Clinic, North Haven · 7 mi away
About Multiple Sclerosis
Multiple sclerosis (MS) slows down or blocks messages between the brain and body. MS can be mild or severe. Learn about MS symptoms and treatment.
More about Multiple Sclerosis on MedlinePlus
Multiple Sclerosis trials in other cities
- New York City, NY17 studies
- Chicago, IL15 studies
- Boston, MA14 studies
- Washington, DC13 studies
- Cleveland, OH10 studies
- Birmingham, AL9 studies
- Aurora, CO8 studies
- Kansas City, KS8 studies
- St. Louis, MO8 studies
- San Francisco, CA8 studies
- Tampa, FL7 studies
- Dallas, TX7 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer40 studies
- Breast Cancer38 studies
- Cancer (all types)35 studies
- Lung Cancer24 studies
- Colorectal Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Metastatic Cancer22 studies
- Prostate Cancer22 studies
- Ovarian Cancer20 studies
- Opioid Overdose19 studies
- Acute Myeloid Leukemia18 studies
- Alcohol Use Disorder (AUD)18 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.